Search Results – Inserm Transfert

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

BIO13408-T1

Drug Field of development:

Acute Myelocytic Leukemia (AML) Therapy Area:

Method Type of patent:

Retinoic acid and arsenic trioxide trigger degradation of mutated

The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present […]

BIO20350-D1

Biomarker Field of development:

Acute Myelocytic Leukemia (AML) Therapy Area:

Method Type of patent:

Use of cd160 as a biomarker in acute myeloid leukemia

Natural killer (NK) cells are innate cytotoxic lymphoid cells (ILCs) involved in the killing of infected and tumor cells. Several NK cell subsets have […]

BIO18281-D1

Biomarker Field of development:

Acute Myelocytic Leukemia (AML) Therapy Area:

Target Type of patent:

Method of treatment and pronostic of acute myeloid leukemia

The present invention relates to the treatment of AML. The inventors previously discovered a new epigenetic biomarker in a cohort of CN-AML patients; […]

BIO18285-T1

Drug Field of development:

Acute Myelocytic Leukemia (AML) Therapy Area:

Method Type of patent:

Targeting myeloperoxidase overcomes cytarabine resistance in human

Chemotherapy commonly alters cellular redox balance and increases the oxidative state. Recent studies have reported that chemoresistant cells have an […]

BIO14117-T1

Drug Field of development:

Acute Myelocytic Leukemia (AML) Therapy Area:

Target Type of patent:

Cdc25a phosphatase inhibitor for use in thetreatment of a drug

The invention relates to a CDC25A phosphatase inhibitor for use in the treatment of drug resistant cancer or for use in the prevention of tumor […]

147

56

310

46

Our Technology Offers

Retinoic acid and arsenic trioxide trigger degradation of mutated

Use of cd160 as a biomarker in acute myeloid leukemia

Method of treatment and pronostic of acute myeloid leukemia

Targeting myeloperoxidase overcomes cytarabine resistance in human

Cdc25a phosphatase inhibitor for use in thetreatment of a drug

You might also be interested in

Vdac1 inhibition for the treatment of peripheral

Pyk2-based gene therapy gene therapy attenuates

Pyk2-based gene therapy attenuates cognitive

Methods and composition to identify and treat

Compounds targeting hsp110 protein for cancer

Selective pharmacological inhibition of epac1 for

Nanoparticles for treating or preventing a

Methods and pharmaceutical compositions for the

Methods and compositions for modulating

Use of mast cell stabilizer for the treatment of

Correction of beta-thalassemia phenotype by

Use of inhibitors of phosphatase activity of

Contact

Inserm Transfert